Type B insulin resistance complicated with systemic lupus erythematosus.

Type B insulin resistance is characterized by the appearance of autoantibodies to the insulin receptor. We present a 59-year-old Japanese man with type B insulin resistance complicated with systemic lupus erythematosus (SLE). A high titer of anti-insulin receptor autoantibodies was revealed when SLE was defined as active disease. Intravenous boluses of cyclophosphamide (IVCY) with oral prednisolone and cyclosporin A induced remission of SLE, and a subsequent disappearance of anti-insulin receptor autoantibodies, followed by a recovery of glucose intolerance. This is a rare and important case report showing a clear correlation between anti-insulin receptor autoantibodies of type B insulin resistance and SLE disease activity.
AuthorsShin-Ya Kawashiri, Atsushi Kawakami, Keita Fujikawa, Naoki Iwamoto, Toshiyuki Aramaki, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Hiroaki Ida, Katsumi Eguchi
JournalInternal medicine (Tokyo, Japan) (Intern Med) Vol. 49 Issue 5 Pg. 487-90 ( 2010) ISSN: 1349-7235 [Electronic] Japan
PMID20190490 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Autoantibodies
  • Immunosuppressive Agents
  • Cyclosporine
  • Cyclophosphamide
  • Prednisolone
  • Receptor, Insulin
  • Autoantibodies (blood)
  • Cyclophosphamide (therapeutic use)
  • Cyclosporine (therapeutic use)
  • Drug Therapy, Combination
  • Glucose Intolerance (complications, immunology)
  • Humans
  • Immunosuppressive Agents (therapeutic use)
  • Insulin Resistance (immunology)
  • Lupus Erythematosus, Systemic (diagnosis, drug therapy, immunology)
  • Male
  • Middle Aged
  • Prednisolone (therapeutic use)
  • Receptor, Insulin (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: